The most prevalent system of receptors in the body. An untapped therapeutic potential in a wide range of disease areas. The ability to rapidly create new and improved cannabinoid drugs, screen them for potential, and bring them to market. The first modern drug discovery platform that targets the human endocannabinoid system. The future of cannabinoid medicine.
The endocannabinoid system is the most prevalent system of receptors in the body, and the reason why “medical” cannabis is successful at treating a wide range of diseases. Current approaches to “medical” cannabis are often misguided and too focused on the plant. This focus ignores modern approaches to medicine, the regulatory pathways to FDA approval, and the complex formularies of drug reimbursements by insurers. When (or if) the US re-schedules cannabis, this would not change the way the FDA approves drugs. The FDA has only ever approved two botanical drugs, and both of these were refined isolates of one ingredient, whereas cannabis has hundreds of ingredients. The two cannabis drugs coming to the US market soon are botanical isolates, and will likely be approved, but will underperform in the market due to their high production cost and lack of insurer reimbursements. The future isn't using plant-based production. Modern drug production methods like biosynthesis have been used for nearly a century to produce pharmaceutical ingredients and vitamins. The technology to produce cannabinoids like CBD and CBG through biosynthesis already exists, and though this is a breakthrough, the real potential is in making future cannabinoid molecules. Much of modern drug discovery is performed through biosynthesis. Modern drug discovery companies are successfully using biosynthesis to create and test new molecules for therapeutic potential. Modern drug discovery is creating tens of thousands of novel molecules each year, screening them for therapeutic potential, then licensing them to large pharmaceutical manufacturers. The value of applying a modern approach to the cannabinoid receptors is enormous.
Indication BioScience will begin by licensing the first of our Statin+ drug concepts, Atorva+. Based on traditional benchmarking methods, we expect initial payment sufficient to pay a significant dividend to investors, and to fund further development. The next major steps post-revenue will include further development of additional Statin+ drugs, an IPO to a major exchange, and the full build-out of the biosynthesis capability. The biosynthesis platform will not only discover next generation drugs, but also develop valuable production technology. Indication BioScience also expects through the course of work in biosynthesis to create proprietary technologies valuable in the production of existing phytocannabinoids such as CBD, and license these to manufacturers.
Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering pharmaceuticals, and are among the most widely prescribed class of drugs. Statins have been found to reduce cardiovascular disease and mortality in those who are at high risk, but also are associated with unwanted side effects. Indication BioScience has pioneered a new formulation platform for statins, Statin+ that increases effectiveness while decreasing side effects.